Skip to content

Efficacy of Direct Selective Laser Trabeculoplasty in Clinical Practice in Patients with Glaucoma

Efficacy of Direct Selective Laser Trabeculoplasty in Clinical Practice in Patients with Glaucoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06808633
Enrollment
30
Registered
2025-02-05
Start date
2025-03-01
Completion date
2026-09-20
Last updated
2025-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Keywords

glaucoma, direct selective laser trabeculoplasty

Brief summary

Prospective, single-arm, single-center, non-randomized, non-comparative study including naïve patients attending our center diagnosed with glaucoma, who have been recommended treatment with direct selective laser trabeculoplasty (DSLT) by their ophthalmologist and who are under no hypotensive medication. DSLT treatment will be performed with the Voyager DSLT system; it will consist of the application of 120 laser pulses of preset 3 ns and a preset 400 μm spot size, with an energy of 1.8 mJ delivered to the limbus through a full 360 degrees. The study will evaluate the effect of DSLT on intraocular pressure (IOP). Baseline IOP will be the IOP measured with Goldman applanation tonometry by the investigator on the day of treatment, prior to the application of DSLT. Patients will be seen one week (±2 days), one month (±7 days), three months (±15 days), six months (±30 days) and 12 months (±40 days) after DSLT treatment. In each of these visits, the attending ophthalmologist will measure IOP with Goldmann applanation tonometry and record the presence of any relevant ocular signs and query patients regarding potential adverse events. The study´s main end-point will be percentage reduction in IOP six months after DSLT compared to baseline.

Interventions

None listed

Sponsors

Clínica Rementería
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• Age over 18 years • Diagnosis of open angle glaucoma in eye study and scheduled for both eyes being treated after bilateral laser indication. The diagnosis of glaucoma will be based on the presence of optic nerve damage that is compatible with glaucoma in the absence of any other cause that could have produced this damage, with an IOP value\>21 mmHg.

Exclusion criteria

* Patients diagnosed with uveitis, angle closure or congenital glaucoma. * Presence of anterior peripheral synechiae * Patients unable to complete three, six- and 12-months follow-up. * Patients having undergone intraocular surgery, save for uneventful phacoemulsification (performed at least 6 months prior to inclusion)

Design outcomes

Primary

MeasureTime frameDescription
Percentage change in IOP six months after DSLT compared to baseline.6 months after DLST applicationPercentage change in IOP six months after DSLT compared to baseline.

Secondary

MeasureTime frameDescription
Percentage change in washed-out IOP 3 and 12 months after DSLT compared to baseline.12 monthsPercentage change in washed-out IOP 3 and 12 months after DSLT compared to baseline.
Mean washed-out IOP change 3, 6 and 12 months after DSLT compared to baseline.12 monthsMean washed-out IOP change 3, 6 and 12 months after DSLT compared to baseline.
Percentage of patients using hypotensive topical treatment after DSLT at 3, 6, and 12 months12 monthsPercentage of patients using hypotensive topical treatment after DSLT at 3, 6, and 12 months
Mean number of medications 3, 6 and 12 months after DSLT (accounting for those on no medications as well when calculating the average).12 monthsMean number of medications 3, 6 and 12 months after DSLT (accounting for those on no medications as well when calculating the average).
Proportion of participants with at least 20% reduction in washed-out IOP from baseline at 3, 6 and 12 months.12 monthsProportion of participants with at least 20% reduction in washed-out IOP from baseline at 3, 6 and 12 months.

Other

MeasureTime frameDescription
Glaucoma Quality of Life-15 Questionnaire at 12 months after DSLT.12 monthsGlaucoma Quality of Life-15 Questionnaire at 12 months after DSLT. It consists of 15 questions asking about patients difficulty for performing everyday tasks, which the patient must grade from 1 to 5, with 1 being that patient has no difficulty performing the task and 5 that he has severe diificulties. Values range from 15 (no difficulties for any activity) to 45 (has severe difficulties for performing all activities)

Countries

Spain

Contacts

Primary ContactInés Contreras
contreras@clinicarementeria.es+34913083838

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026